Drug Dependence Clinical Trial
Official title:
Brain Activation in Response to Motivational and Affective Stimuli: Pharmacological Manipulations
This study seeks more information about the biology of substance dependency by exploring the
brain areas involved in feeling positive and negative emotions. Specifically, it will
determine whether a brain chemical called dopamine affects activity in certain brain regions
during performance of a game that involves winning and losing money. Brain activity will be
examined using magnetic resonance imaging (MRI), a test that uses a magnetic field and radio
waves to produce images of brain structure and function.
Young to middle-aged healthy adults may participate in this study. Candidates will be
screened with a medical history, physical examination, electrocardiogram (EKG), psychiatric
interview, and blood and urine tests. Participants will be assigned to one of the two study
procedures, as follows:
Tyrosine/Phenylalanine
This study requires two overnight stays at the NIH Clinical Center. For each stay, subjects
are admitted to the hospital the afternoon before the MRI scan. From the time of admission
until after the scan, their diets are restricted to food relatively low in amino acids,
prepared by NIH dietitians. The next day, participants undergo MRI scanning. For this
procedure, the subject lies on a table that is moved into the scanner, a metal cylindrical
machine. Earplugs are worn to muffle loud noises that occur with electrical switching of the
radio frequency circuits. Imaging of brain structure takes about 10 to 15 minutes. Additional
scans are then taken to measure brain activity while the subject plays simple computer games
for money. These scans take about another 20 to 45 minutes. Five hours before the MRI, the
subject drinks one of two beverages containing amino acids. A different beverage is given for
each of the two visits: one drink lacks the essential amino acids tyrosine and phenylalanine,
from which the body makes dopamine; the other contains balanced amounts of these two amino
acids. Finally, subjects fill out mood-rating questionnaires before and after drinking each
of the beverages.
Dextroamphetamine
This study requires two outpatient visits to the NIH Clinical Center. For one visit,
participants are given an injection of 0.2 mg/kg body weight of the drug dextroamphetamine;
for the other, they are given an injection of saline (salt water). After each injection, they
undergo MRI scanning while playing computer games for money, as described above. They will
fill out mood-rating questionnaires before and after each brain scan.
The purpose of this protocol is to advance the understanding of the behavioral neurobiology
underlying substance dependency by exploring regional brain activity in response to
appetitive and aversive stimuli in human subjects. In this protocol, brain activation is the
dependent measure, as measured by blood oxygenation level dependent (BOLD) signal acquired
during functional magnetic resonance (fMRI) imaging. Previous work in this laboratory has
found that cues of anticipated monetary reward versus threat of negative reinforcement causes
increased BOLD signal in the nucleus accumbens (NAcc) and other parts of the ventral
striatum. This protocol is intended to extend these findings by exploring whether the
recently reported BOLD activation (a hemodynamic response) in certain brain regions in
response to motivational cues can be perturbed by dopaminergic pharmacological manipulations.
In a series of two, repeated-measures, within-subject experiments, we propose to temporarily
alter subjects' brain monoamine neurotransmitter systems with pharmacological interventions
prior to presenting the subjects with appetitive and aversive visual stimuli as well as cues
signaling potential punishment and reward. In the first experiment, brain catecholamine
systems will be deactivated by dietary restrictions of amino acid precursors Tyrosine (Tyr)
and Phenylalanine (Phe), respectively. In the second experiment, the brain dopamine (DA)
release will be transiently increased with administration of dextroamphetamine (Amph). Based
on a wealth of existent findings, we predict that acutely enhancing synaptic DA by Amph will
augment reward-elicited activation in the ventral striatum. Conversely, acute dietary
restriction of the DA precursor Tyr, (along with Tyr precursor Phe) will blunt this
activation. Since substance use disorders (SUD) such as alcoholism may result from disordered
neural systems regulating approach and avoidance behavior (with respect to the substance),
this experiment can yield useful knowledge relevant to SUD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT00593463 -
Drug Discrimination in Methadone-Maintained Humans Study 1
|
Phase 1 | |
Completed |
NCT03678051 -
CBT4CBT for Women in Residential Treatment for Substance Use Disorders
|
N/A | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
Completed |
NCT01449981 -
Development and Testing of Adolescent Twelve-Step Facilitation
|
N/A | |
Completed |
NCT00183118 -
Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03333460 -
Transcranial Magnetic Stimulation for Cocaine Addiction
|
N/A | |
Completed |
NCT02124980 -
Automated Recovery Line for Medication Assisted Treatment
|
N/A | |
Terminated |
NCT00975416 -
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence
|
Phase 4 | |
Completed |
NCT00265512 -
LINK: Aftercare Monitoring Project
|
N/A | |
Completed |
NCT00706901 -
Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans
|
N/A | |
Completed |
NCT02656745 -
Clinical Trial of Smoking Cessation Mobile Phone Program
|
N/A | |
Withdrawn |
NCT00675532 -
Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).
|
N/A | |
Active, not recruiting |
NCT03539575 -
CB1R in Synthetic Psychoactive Cannabinoids
|
N/A | |
Completed |
NCT01246401 -
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
|
Phase 1/Phase 2 | |
Completed |
NCT01096550 -
Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
|
N/A | |
Completed |
NCT00605033 -
A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
|
Phase 4 |